# ACADIA PHARMACEUTICALS INC. (ACAD) FY2026 YTD Q2 P&L / Income Statement

- Company: ACADIA PHARMACEUTICALS INC. (ACAD)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001193125-26-333243
- Page: https://plicit.ai/financials/acad/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/acad-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Business Segment by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 576,021,000 US dollars
- **Cost of product sales**: 53,107,000 US dollars
- **Gross profit (calculated)**: 522,914,000 US dollars
- **Operating expenses (calculated)**: 489,694,000 US dollars
- **Income from operations**: 33,220,000 US dollars
- **Other income (expense), net (calculated)**: 17,234,000 US dollars
- **Income before income taxes**: 50,454,000 US dollars
- **Income tax expense**: 15,317,000 US dollars
- **Net loss**: 35,137,000 US dollars
- **Reportable Segment - DAYBUE products**: 225,965,000 US dollars
- **Reportable Segment - NUPLAZID**: 350,056,000 US dollars
- **Research and development**: 158,423,000 US dollars
- **Selling, general and administrative**: 331,271,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Customer

- Page: https://plicit.ai/financials/acad/fy2026-ytd-q2-income-statement/revenue-by-customer
- Chart image: https://plicit.ai/charts/acad-fy2026-ytd-q2-revenue-by-customer-sankey.png

Income statement for 2026-01-01 through 2026-06-30. View: Customer. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 576,021,000 US dollars
- **Cost of product sales**: 53,107,000 US dollars
- **Gross profit (calculated)**: 522,914,000 US dollars
- **Operating expenses (calculated)**: 489,694,000 US dollars
- **Income from operations**: 33,220,000 US dollars
- **Other income (expense), net (calculated)**: 17,234,000 US dollars
- **Income before income taxes**: 50,454,000 US dollars
- **Income tax expense**: 15,317,000 US dollars
- **Net loss**: 35,137,000 US dollars
- **NUPLAZID**: 350,056,000 US dollars
- **DAYBUE products**: 225,965,000 US dollars
- **Research and development**: 158,423,000 US dollars
- **Selling, general and administrative**: 331,271,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.